Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1521

Sort by

Sort Order Select

Journal Articles

Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis

Blood (2020) 135 (19): 1696–1703.

https://doi.org/10.1182/blood.2019003347

Published: 2020

Includes: Supplemental data

Journal Articles

Description of a knock-in mouse model of JAK2 V617F MPN emerging from a minority of mutated hematopoietic stem cells

Olivier Mansier, Badr Kilani, Amélie V. Guitart, Alexandre Guy, Virginie Gourdou-Latyszenok, Caroline Marty, Marie Parrens, Isabelle Plo, William Vainchenker, Chloé James

Blood (2019) 134 (26): 2383–2387.

https://doi.org/10.1182/blood.2019001163

Published: 2019

Includes: Supplemental data

Journal Articles

JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera

Blood (2019) 134 (26): 2388–2398.

https://doi.org/10.1182/blood.2019001385

Published: 2019

Includes: Supplemental data

Journal Articles

Aberrant Responsiveness of Erythropoiesis to Iron Deficiency in Polycythemia Vera

Maria Feola, PhD, Daniel Moskop, Nada Terra, Young C. Park, Andrew Dunbar, MD, Ross L. Levine, MD, Ronald Hoffman, MD, Yelena Ginzburg, MD

Blood (2019) 134 (Supplement_1): 429.

https://doi.org/10.1182/blood-2019-131095

Published: 2019

Journal Articles

Thromboembolic Risk Reduction and High Rate of Complete Molecular Response with Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: Results from a Randomized Controlled Study

Jean-Jacques Kiladjian, MD PhD, Christoph Klade, PhD, Pencho Georgiev, MD, Dorota Krochmalczyk, MD, Liana Gercheva-Kyuchukova, MD, Miklos Egyed, Viktor Rossiev, MD, Petr Dulicek, MD, Árpád Illés, MD D.Sc, Halyna Pylypenko, MD, Lylia Sivcheva, MD, Jiri Mayer, MD, Vera Yablokova, MD, Kurt Krejcy, MD, Hans Hasselbalch, MD, Robert Kralovics, PhD, Heinz Gisslinger, MD

Blood (2019) 134 (Supplement_1): 553.

https://doi.org/10.1182/blood-2019-122233

Published: 2019

Journal Articles

Landscape of TP53 Mutations in MPN

Noushin Farnoud, PhD, Christopher Famulare, MS, Elli Papaemmanuil, PhD, Erin McGovern, BA, Juan Medina, MS, Juan E. Arango Ossa, BS, Raajit K. Rampal, MD PhD, Bing Li, MD, Ross L. Levine, MD, John Mascarenhas, MD, Rona Singer Weinberg, PhD, Minal A Patel, MPH, Ronald Hoffman, MD

Blood (2019) 134 (Supplement_1): 1681.

https://doi.org/10.1182/blood-2019-132014

Published: 2019

Journal Articles

Exon-Level Genomic Abnormalities Are Frequent in Cytogenetically Normal Patients with Philadelphia-Chromosome Negative Myeloproliferative Neoplasms (MPNs)

Joseph Tripodi, Douglas Tremblay, MD, Ronald Hoffman, MD, Umut Ozbek, PhD, John Mascarenhas, MD, Marina Kremyanskaya, Vesna Najfeld, PhD

Blood (2019) 134 (Supplement_1): 1687.

https://doi.org/10.1182/blood-2019-128948

Published: 2019

Journal Articles

Highly Reduced Survival in ET and PV Patients with Vascular Complications during Follow-up - Real World Data from the Swedish MPN Registr

Marie Lindgren, Erik Ahlstrand, MD PhD, Helna Pettersson, MD, Maria Liljeholm, Anna Ravn-Landtblom, MD, Stefan Scheding, Prof, Björn Andréasson, MD PhD, Jan Samuelsson, MD PhD

Blood (2019) 134 (Supplement_1): 1658.

https://doi.org/10.1182/blood-2019-124374

Published: 2019

Journal Articles

Germline Genetic Factors Affecting Interferon Alpha Therapy in Polycythemia Vera

Roland Jäger, PhD, Elisabeth Fuchs, Edith Bogner, Jelena D. Milosevic Feenstra, PhD, Kurt Krejcy, MD, Christoph Klade, PhD, Michael Zoerer, PhD, Heinz Gisslinger, MD, Robert Kralovics, PhD

Blood (2019) 134 (Supplement_1): 1685.

https://doi.org/10.1182/blood-2019-130139

Published: 2019

Journal Articles

Pegylated Interferon-Alfa Suppresses Clonal Hematopoiesis in Polycythemia Vera and Essential Thrombocythemia and Is Associated with Immune Responses to Tumor Antigens

Tsewang Tashi, MD, Tim Luetkens, MD, Stephanie Avila, Soo Jin Kim, MS, Josef T. Prchal, MD

Blood (2019) 134 (Supplement_1): 1691.

https://doi.org/10.1182/blood-2019-131974

Published: 2019

Journal Articles

Evaluation of Virus-Specific T Cell Responses in Patients Affected with Myeloproliferative Neoplasms Treated with Ruxolitinib

Elisa Rumi, MD, Chiara Cavalloni, MD, Giuditta Comolli, Virginia Valeria Ferretti, Irene Cassaniti, Daniela Pietra, PhD, Chiara Trotti, MD, Michele Ciboddo, MD, Melania Degli Antoni, Milena Furione, Fausto Baldanti, MD, Luca Arcaini, Mario Cazzola, MD

Blood (2019) 134 (Supplement_1): 1660.

https://doi.org/10.1182/blood-2019-127994

Published: 2019

Journal Articles

Recombinant Interferon-α Reduces Thrombotic Events in Patients with Polycythemia Vera

Spencer Krichevsky, BS, Ghaith Abu Zeinah, MD, Claudia Sosner, BA, Diana Jaber, BA, Niamh Savage, BA, Gabriela Hoberman, BA, Ellen K. Ritchie, MD, Andrew I. Schafer, MD, Richard T. Silver, MD, Joseph Scandura, MD PhD

Blood (2019) 134 (Supplement_1): 1664.

https://doi.org/10.1182/blood-2019-131605

Published: 2019

Journal Articles

US Optum Database Study in Polycythemia Vera Patients: Thromboembolic Events (TEs) with Hydroxyurea (HU) Vs Ruxolitinib Switch Therapy and Machine-Learning Model to Predict Incidence of Tes and HU Failure

Srdan Verstovsek, MD PhD, Valerio De Stefano, MD, Florian H. Heidel, MD, Mike Zuurman, PhD, Michael Zaiac, MD, Erwan Bigan, PhD, Michael Ruhl, PhD, Christoph Meier, PhD, Magali Beffy, PhD, Jean-Jacques Kiladjian, MD PhD

Blood (2019) 134 (Supplement_1): 1659.

https://doi.org/10.1182/blood-2019-126410

Published: 2019

Journal Articles

A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Patients with Relapsed/Refractory Multiple Myeloma (MM)

James R. Berenson, MD, Jennifer To, BS, Tanya M. Spektor, PhD, Daisy Martinez, Armando J. Sanchez, MBA, Carley Turner, CCRP, Regina Swift, Benjamin Eades, PharmD, Gary Schwartz, MD, Shahrooz Eshaghian, MD, Laura V. Stampleman, Robert A. Moss, MD, Youram Nassir, MD, Ravindranath Patel, MD, Alberto Bessudo, MD, Daniel Greenwald, MD, Ralph V. Boccia, MD, Stephen Lim, MD, Robert Vescio, MD

Blood (2019) 134 (Supplement_1): 1903.

https://doi.org/10.1182/blood-2019-131370

Published: 2019

Journal Articles

Identifying Cytokine Biomarkers of Response to Pegylated-Interferon Therapy in Polycythemia Vera and Essential Thrombocythemia: Correlative Analysis from the MPN-RC 111/112 Trials

Andrew Dunbar, MD, Heidi E. Kosiorek, MS, Aishwarya Krishnan, Erin McGovern, BA, Young Park, BS, Minal A Patel, MPH, Rona Singer Weinberg, PhD, Abdulraheem Yacoub, MD, Amylou C. Dueck, PhD, John Mascarenhas, MD, Ross L. Levine, MD, Ronald Hoffman, MD, Raajit K. Rampal, MD PhD

Blood (2019) 134 (Supplement_1): 1661.

https://doi.org/10.1182/blood-2019-129571

Published: 2019

Journal Articles

Patient-Reported Outcomes (PRO) Data from Patients (Pts) with Essential Thrombocythemia (ET) Enrolled in the MOST Study

Ellen K. Ritchie, MD, Anas Al-Janadi, MD, Philomena Colucci, DO, MS, Patricia Kalafut, PhD, Dilan Paranagama, PhD, Ruben A. Mesa, MD

Blood (2019) 134 (Supplement_1): 1665.

https://doi.org/10.1182/blood-2019-124527

Published: 2019

Journal Articles

Multi-Lineage Dysplasia Assessment By Immunophenotype in Myeloproliferative Neoplasms (MPN): Correlation with Disease' Variant, Clinical Features and Molecular Genetics

Francesco Mannelli, MD, Sara Bencini, Benedetta Peruzzi, Paola Guglielmelli, MD PhD, Annalisa Pacilli, PhD, Giada Rotunno, PhD, Francesca Gesullo, BSci, Blerina Jance, Marida Bonetti, Roberto Caporale, Francesco Annunziato, PhD, Alessandro M. Vannucchi, MD

Blood (2019) 134 (Supplement_1): 1668.

https://doi.org/10.1182/blood-2019-125843

Published: 2019

Journal Articles

Real World Data on Obstetric (OC) and Maternal Complications (MC) Occurring in a Cohort of Patients with Ph Negative Myeloproliferative Neoplasms (MPN): Argentinian Multicentric Study

Blood (2019) 134 (Supplement_1): 1669.

https://doi.org/10.1182/blood-2019-131778

Published: 2019

Journal Articles

The Impact of the 2011 European Leukemianet (ELN) Guidelines for Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms on Therapeutic Phlebotomy and Hydroxyurea Use in Patients with Polycythemia Vera and Essential Thrombocythemia

Nikolai A. Podoltsev, MD PhD, Rong Wang, PhD, Rory M Shallis, MD, Scott F. Huntington, MD MPH, Amer M. Zeidan, MBBS, MHS, Steven D. Gore, MD, Amy J Davidoff, PhD MS, Xiaomei Ma, PhD

Blood (2019) 134 (Supplement_1): 2125.

https://doi.org/10.1182/blood-2019-127563

Published: 2019

Journal Articles

Patient Reported Financial Toxicity in Myeloproliferative Neoplasms

Thomas G. Knight, MD, Myra Robinson, MS, Jing Ai, MD PhD, Brittany K Ragon, MD, Rhonda Davis, RN, BSN, Cindy Shiflett, LPN, Erica Ruston, RN, BSN, Hailey Glover, RN, BSN, Jigar Trivedi, MSc, PharmD, Belinda R Avalos, MD, Jonathan M. Gerber, MD, James T Symanowski, PhD, Edward A Copelan, Michael R. Grunwald, MD

Blood (2019) 134 (Supplement_1): 2099.

https://doi.org/10.1182/blood-2019-128858

Published: 2019

NARROW

Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis

Description of a knock-in mouse model of JAK2 V617F MPN emerging from a minority of mutated hematopoietic stem cells

JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera

Aberrant Responsiveness of Erythropoiesis to Iron Deficiency in Polycythemia Vera

Thromboembolic Risk Reduction and High Rate of Complete Molecular Response with Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: Results from a Randomized Controlled Study

Landscape of TP53 Mutations in MPN

Exon-Level Genomic Abnormalities Are Frequent in Cytogenetically Normal Patients with Philadelphia-Chromosome Negative Myeloproliferative Neoplasms (MPNs)

Highly Reduced Survival in ET and PV Patients with Vascular Complications during Follow-up - Real World Data from the Swedish MPN Registr

Germline Genetic Factors Affecting Interferon Alpha Therapy in Polycythemia Vera

Pegylated Interferon-Alfa Suppresses Clonal Hematopoiesis in Polycythemia Vera and Essential Thrombocythemia and Is Associated with Immune Responses to Tumor Antigens

Evaluation of Virus-Specific T Cell Responses in Patients Affected with Myeloproliferative Neoplasms Treated with Ruxolitinib

Recombinant Interferon-α Reduces Thrombotic Events in Patients with Polycythemia Vera

US Optum Database Study in Polycythemia Vera Patients: Thromboembolic Events (TEs) with Hydroxyurea (HU) Vs Ruxolitinib Switch Therapy and Machine-Learning Model to Predict Incidence of Tes and HU Failure

A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Patients with Relapsed/Refractory Multiple Myeloma (MM)

Identifying Cytokine Biomarkers of Response to Pegylated-Interferon Therapy in Polycythemia Vera and Essential Thrombocythemia: Correlative Analysis from the MPN-RC 111/112 Trials

Patient-Reported Outcomes (PRO) Data from Patients (Pts) with Essential Thrombocythemia (ET) Enrolled in the MOST Study

Multi-Lineage Dysplasia Assessment By Immunophenotype in Myeloproliferative Neoplasms (MPN): Correlation with Disease' Variant, Clinical Features and Molecular Genetics

Real World Data on Obstetric (OC) and Maternal Complications (MC) Occurring in a Cohort of Patients with Ph Negative Myeloproliferative Neoplasms (MPN): Argentinian Multicentric Study

The Impact of the 2011 European Leukemianet (ELN) Guidelines for Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms on Therapeutic Phlebotomy and Hydroxyurea Use in Patients with Polycythemia Vera and Essential Thrombocythemia

Patient Reported Financial Toxicity in Myeloproliferative Neoplasms

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only